Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells

American Journal of Pathology

Volumn 180, Issue 3, 2012, Pages 1179-1188

  Sheu, Jim Jinn Chyuan ^a,b   Guan, Bin ^c   Tsai, Fuu Jen ^a   Hsiao, Erin Yi Ting ^a   Chen, Chih Mei ^a   Seruca, Raquel ^d   Wang, Tian Li ^c   Shih, Ie Ming ^c  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CHECKPOINT KINASE 2; GLUCOSE TRANSPORTER 1; HISTONE H2AX; K RAS PROTEIN; P21 ACTIVATED KINASE; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; GENE MUTATION; ONCOGENE K RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; UPREGULATION;

APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA BREAKS; EPITHELIAL CELLS; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84863152979     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.11.026     Document Type: Article

References (57)

1. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M.J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B.A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G.J. Riggins, D.D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J.W. Ho, S.Y. Leung, S.T. Yuen, B.L. Weber, H.F. Seigler, T.L. Darrow, H. Paterson, R. Marais, C.J. Marshall, R. Wooster, M.R. Stratton, P.A. Futreal Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
2. Y. Cohen, M. Xing, E. Mambo, Z. Guo, G. Wu, B. Trink, U. Beller, W.H. Westra, P.W. Ladenson, D. Sidransky BRAF mutation in papillary thyroid carcinoma J Natl Cancer Inst 95 2003 625 627
3. E.T. Kimura, M.N. Nikiforova, Z. Zhu, J.A. Knauf, Y.E. Nikiforov, J.A. Fagin High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTCRAS- BRAF signaling pathway in papillary thyroid carcinoma Cancer Res 63 2003 1454 1457
4. J.D. Schiffman, J.G. Hodgson, S.R. VandenBerg, P. Flaherty, M.Y. Polley, M. Yu, P.G. Fisher, D.H. Rowitch, J.M. Ford, M.S. Berger, H. Ji, D.H. Gutmann, C.D. James Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas Cancer Res 70 2010 512 519
5. G. Singer, R. Oldt 3rd, Y. Cohen, B.G. Wang, D. Sidransky, R.J. Kurman, M. Shih Ie Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 95 2003 484 486
6. H. Ji, Z. Wang, S.A. Perera, D. Li, M.C. Liang, S. Zaghlul, K. McNamara, L. Chen, M. Albert, Y. Sun, R. Al-Hashem, L.R. Chirieac, R. Padera, R.T. Bronson, R.K. Thomas, L.A. Garraway, P.A. Janne, B.E. Johnson, L. Chin, K.K. Wong Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models Cancer Res 67 2007 4933 4939
7. J. Downward Targeting RAS signalling pathways in cancer therapy Nat Rev Cancer 3 2003 11 22
8. T. Rajakulendran, M. Sahmi, M. Lefrancois, F. Sicheri, M. Therrien A dimerizationdependent mechanism drives RAF catalytic activation Nature 461 2009 542 545
9. H. Rajagopalan, A. Bardelli, C. Lengauer, K.W. Kinzler, B. Vogelstein, V.E. Velculescu Tumorigenesis: rAF/RAS oncogenes and mismatch-repair status Nature 418 2002 934
10. D.B. Solit, L.A. Garraway, C.A. Pratilas, A. Sawai, G. Getz, A. Basso, Q. Ye, J.M. Lobo, Y. She, I. Osman, T.R. Golub, J. Sebolt-Leopold, W.R. Sellers, N. Rosen BRAF mutation predicts sensitivity to MEK inhibition Nature 439 2005 358 362
11. G. Pohl, C.L. Ho, R.J. Kurman, R. Bristow, T.L. Wang, M. Shih Ie Inactivation of the mitogenactivated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations Cancer Res 65 2005 1994 2000
12. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. Jouary, D. Schadendorf, A. Ribas, S.J. O'Day, J.A. Sosman, J.M. Kirkwood, A.M. Eggermont, B. Dreno, K. Nolop, J. Li, B. Nelson, J. Hou, R.J. Lee, K.T. Flaherty, A.G. McArthur Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
13. A. Vultur, J. Villanueva, M. Herlyn BRAF inhibitor unveils its potential against advanced melanoma Cancer Cell 18 2010 301 302
14. A. Vultur, J. Villanueva, M. Herlyn Targeting BRAF in advanced melanoma: a first step toward manageable disease Clin Cancer Res 17 2011 1658 1663
15. J. Villanueva, A. Vultur, J.T. Lee, R. Somasundaram, M. Fukunaga-Kalabis, A.K. Cipolla, B. Wubbenhorst, X. Xu, P.A. Gimotty, D. Kee, A.E. Santiago-Walker, R. Letrero, K. D'Andrea, A. Pushparajan, J.E. Hayden, K.D. Brown, S. Laquerre, G.A. McArthur, J.A. Sosman, K.L. Nathanson, M. Herlyn Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 18 2010 683 695
16. D.A. Tuveson, B.L. Weber, M. Herlyn BRAF as a potential therapeutic target in melanoma and other malignancies Cancer Cell 4 2003 95 98
17. M. Shih Ie, R.J. Kurman Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis Am J Pathol 164 2004 1511 1518
18. K.R. Cho, M. Shih Ie Ovarian cancer Annu Rev Pathol 4 2009 287 313
19. K. Nakayama, N. Nakayama, R.J. Kurman, L. Cope, G. Pohl, Y. Samuels, V.E. Velculescu, T.L. Wang, M. Shih Ie Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms Cancer Biol Ther 5 2006 779 785
20. N.L. Sieben, P. Macropoulos, G.M. Roemen, S.M. Kolkman-Uljee, G. Jan Fleuren, R. Houmadi, T. Diss, B. Warren, M. Al Adnani, A.P. De Goeij, T. Krausz, A.M. Flanagan In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours J Pathol 202 2004 336 340
21. S. Jones, T.L. Wang, R.J. Kurman, K. Nakayama, V.E. Velculescu, B. Vogelstein, K.W. Kinzler, N. Papadopoulos, I.M. Shih Low-grade serous carcinomas of the ovary contain very few point mutations J Pathol 226 2012 413 420
22. C.-Y. Hsu, R. Bristow, M. Cha, B.G. Wang, C.-L. Ho, R.J. Kurman, T.-L. Wang, M. Shih I- Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas Clin Cancer Res 10 2004 6432 6436
23. N. Nakayama, K. Nakayama, S. Yeasmin, M. Ishibashi, A. Katagiri, K. Iida, M. Fukumoto, K. Miyazaki KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer Br J Cancer 99 2008 2020 2028
24. C.-L. Ho, R.J. Kurman, R. Dehari, T.-L. Wang, I.-M. Shih Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors Cancer Res 64 2004 6915 6918
25. R.P. Charles, G. Lezza, E. Amendola, D. Dankort, M. McMahon Mutationally activated BRAFV600E elicits papillary thyroid cancer in the adult mouse Cancer Res 71 2011 3863 3871
26. J. Yun, C. Rago, I. Cheong, R. Pagliarini, P. Angenendt, H. Rajagopalan, K. Schmidt, J.K. Willson, S. Markowitz, S. Zhou, L.A. Diaz Jr, V.E. Velculescu, C. Lengauer, K.W. Kinzler, B. Vogelstein, N. Papadopoulos Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells Science 325 2009 1555 1559
27. F.T. Kolligs, G. Hu, C.V. Dang, E.R. Fearon Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression Mol Cell Biol 19 1999 5696 5706
28. F.T. Kolligs, M.T. Nieman, I. Winer, G. Hu, D. Van Mater, Y. Feng, I.M. Smith, R. Wu, Y. Zhai, K.R. Cho, E.R. Fearon ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation Cancer Cell 1 2002 145 155
29. T. Komiya, Y. Park, S. Modi, A.B. Coxon, H. Oh, F.J. Kaye Sustained expression of Mect1-Maml2 is essential for tumor cell growth in salivary gland cancers carrying the t(11;19) translocation Oncogene 25 2006 6128 6132
30. G.T. Bommer, C. Jager, E.M. Durr, S. Baehs, S.T. Eichhorst, T. Brabletz, G. Hu, T. Frohlich, G. Arnold, D.C. Kress, B. Goke, E.R. Fearon, F.T. Kolligs DRO1, a gene down-regulated by oncogenes, mediates growth inhibition in colon and pancreatic cancer cells J Biol Chem 280 2005 7962 7975
31. K.W. Foster, S. Ren, I.D. Louro, S.M. Lobo-Ruppert, P. McKie-Bell, W. Grizzle, M.R. Hayes, T.R. Broker, L.T. Chow, J.M. Ruppert Oncogene expression cloning by retroviral transduction of adenovirus E1A-immortalized rat kidney RK3E cells: transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLF Cell Growth Differ 10 1999 423 434
32. N.D. Hendrix, R. Wu, R. Kuick, D.R. Schwartz, E.R. Fearon, K.R. Cho Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas Cancer Res 66 2006 1354 1362
33. J.J. Sheu, B. Guan, J.H. Choi, A. Lin, C.H. Lee, Y.T. Hsiao, T.L. Wang, F.J. Tsai, I.M. Shih Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability J Biol Chem 285 2010 38260 38269
34. N.P. Singh, M.T. McCoy, R.R. Tice, E.L. Schneider A simple technique for quantitation of low levels of DNA damage in individual cells Exp Cell Res 175 1988 184 191
35. M.B. Kastan, J. Bartek Cell-cycle checkpoints and cancer Nature 432 2004 316 323
36. Y. Shiloh ATM and related protein kinases: safeguarding genome integrity Nat Rev Cancer 3 2003 155 168
37. K.M. Haigis, I.I. Wistuba, J.M. Kurie Lung premalignancy induced by mutant B-Raf, what is thy fate? To senesce or not to senesce, that is the question Genes Dev 21 2007 361 366
38. M. Serrano, A.W. Lin, M.E. McCurrach, D. Beach, S.W. Lowe Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a Cell 88 1997 593 602
39. J. Bartkova, Z. Horejsi, K. Koed, A. Kramer, F. Tort, K. Zieger, P. Guldberg, M. Sehested, J.M. Nesland, C. Lukas, T. Orntoft, J. Lukas, J. Bartek DNA damage response as a candidate anticancer barrier in early human tumorigenesis Nature 434 2005 864 870
40. J. Bartkova, N. Rezaei, M. Liontos, P. Karakaidos, D. Kletsas, N. Issaeva, L.V. Vassiliou, E. Kolettas, K. Niforou, V.C. Zoumpourlis, M. Takaoka, H. Nakagawa, F. Tort, K. Fugger, F. Johansson, M. Sehested, C.L. Andersen, L. Dyrskjot, T. Orntoft, J. Lukas, C. Kittas, T. Helleday, T.D. Halazonetis, J. Bartek, V.G. Gorgoulis Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints Nature 444 2006 633 637
41. V.G. Gorgoulis, L.V. Vassiliou, P. Karakaidos, P. Zacharatos, A. Kotsinas, T. Liloglou, M. Venere, R.A. Ditullio Jr, N.G. Kastrinakis, B. Levy, D. Kletsas, A. Yoneta, M. Herlyn, C. Kittas, T.D. Halazonetis Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions Nature 434 2005 907 913
42. K.T. Kuo, B. Guan, Y. Feng, T.L. Mao, X. Chen, N. Jinawath, Y. Wang, R.J. Kurman, I.M. Shih, T.L. Wang Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas Cancer Res 69 2009 4036 4042
43. M.C. Haffner, A.M. De Marzo, A.K. Meeker, W.G. Nelson, S. Yegnasubramanian Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target? Clin Cancer Res 17 2011 3858 3864
44. K.C. Sagun, J.M. Carcamo, D.W. Golde Antioxidants prevent oxidative DNA damage and cellular transformation elicited by the over-expression of c-MYC Mutat Res 593 2006 64 79
45. B. Vogelstein, D. Lane, A.J. Levine Surfing the p53 network Nature 408 2000 307 310
46. G.G. Garzetti, A. Ciavattini, G. Goteri, M. De Nictolis, D. Stramazzotti, G. Lucarini, G. Biagini Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance Gynecol Oncol 56 1995 169 174
47. P.C. Huettner, D.S. Weinberg, J.M. Lage Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry Correlation with prognostic features Am J Pathol 141 1992 699 706
48. G. Singer, R. Sthr, L. Cope, R. Dehari, A. Hartmann, D.F. Cao, T.L. Wang, R.J. Kurman, IeM. Shih Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation Am J Surg Pathol 29 2005 218 224
49. K.M. Haigis, A. Sweet-Cordero New insights into oncogenic stress Nat Genet 43 2011 177 178
50. M. Kato, T. Paranjape, R.U. Muller, S. Nallur, E. Gillespie, K. Keane, A. Esquela-Kerscher, J.B. Weidhaas, F.J. Slack The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells Oncogene 28 2009 2419 2424
51. L. He, X. He, L.P. Lim, E. de Stanchina, Z. Xuan, Y. Liang, W. Xue, L. Zender, J. Magnus, D. Ridzon, A.L. Jackson, P.S. Linsley, C. Chen, S.W. Lowe, M.A. Cleary, G.J. Hannon A microRNA component of the p53 tumour suppressor network Nature 447 2007 1130 1134
52. D. Dankort, E. Filenova, M. Collado, M. Serrano, K. Jones, M. McMahon A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors Genes Dev 21 2007 379 384
53. D. Dankort, D.P. Curley, R.A. Cartlidge, B. Nelson, A.N. Karnezis, W.E. Damsky Jr, M.J. You, R.A. DePinho, M. McMahon, M. Bosenberg Braf(V600E) cooperates with Pten loss to induce metastatic melanoma Nat Genet 41 2009 544 552
54. T. Amann, C. Hellerbrand GLUT1 as a therapeutic target in hepatocellular carcinoma Expert Opin Ther Targets 13 2009 1411 1427
55. D. Marotta, J. Karar, W.T. Jenkins, M. Kumanova, K.W. Jenkins, J.W. Tobias, D. Baldwin, A. Hatzigeorgiou, P. Alexiou, S.M. Evans, R. Alarcon, A. Maity, C. Koch, C. Koumenis In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection Cancer Res 71 2011 779 789
56. T. Kurokawa, Y. Yoshida, K. Kawahara, T. Tsuchida, H. Okazawa, Y. Fujibayashi, Y. Yonekura, F. Kotsuji Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary Int J Cancer 109 2004 926 932
57. A.J. Levine, A.M. Puzio-Kuter The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes Science 330 2010 1340 1344